Dr. McMahon joins Citrus from Inizio, where she was Global President, ApotheCom (an Inizio company).
Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.
The U.S. Supreme Court on Friday overturned the long-standing Chevron doctrine, which required courts to defer to federal agencies and their interpretation of statutes, putting potential limits on the FDA’s regulatory decisions.
Unlike the current commercially available pneumococcal vaccines—including its top competitor, Pfizer’s Prevnar 20—Capvaxive covers eight unique serotypes that together account for around 27% of IPD cases in patients 50 years and older, and approximately 30% of cases in seniors 65 years and older.
The French drugmaker is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported.
AstraZeneca said on Monday that the European Union drug regulator has accepted a market authorization application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated assessment.